ALNY•November 19, 2026 at 12:00 PM UTCPharmaceuticals, Biotechnology & Life Sciences

Regeneron's Livsayis Approval Adds Seventh RNAi Validation, But AMVUTTRA Ramp Remains Core

Read source article

What happened

Alnylam's collaborator Regeneron received FDA approval for Livsayis (cemdisiran) in generalized myasthenia gravis, marking the seventh Alnylam-discovered RNAi therapeutic to reach market in under nine years. This approval triggers milestone and royalty economics under the collaboration, but the revenue impact is modest relative to Alnylam's product franchise; Q3'25 collaboration revenue was $351.7M, with Regeneron contributing only $22.5M. The core investment narrative remains dominated by AMVUTTRA's ATTR-CM scaling, where FY2026 combined net product revenue guidance of $4.9B-$5.3B is the primary bar. At $331, the stock sits in the WAIT zone, with an attractive entry near $300 and trim above $420, as payer/GTN scrutiny and competition from BridgeBio's Attruby persist.

Implication

The Livsayis approval validates platform breadth but adds only a small, predictable royalty stream, dwarfed by product revenue concentration in AMVUTTRA. The primary overhang remains the U.S. Attorney subpoena on government price reporting and distributor fee/discount arrangements, which could force structural GTN concessions across four products. Competitive pressure is intensifying, with BridgeBio reporting 6,629 Attruby prescriptions and 1,632 prescribers as of Dec 31, 2025. Investors should treat any AMVUTTRA revenue miss of $25-35M as a sentiment event, given the stock's demonstrated sensitivity to quarterly beats/misses. Waiting for either a pullback to $300 or two consecutive quarters of clean execution offers better risk-adjusted returns.

Thesis delta

The approval modestly strengthens the RNAi platform story but does not alter the WAIT rating or the key risks of AMVUTTRA execution, subpoena-related GTN compression, and Attruby competition. No material shift in the investment thesis; collaboration revenue remains secondary to the AMVUTTRA growth engine.

Confidence

high